Spun out of King’s College London, AviadoBio is focusing on neurodegenerative diseases and has emerged from stealth with nearly $100m in overall funding.

AviadoBio, a UK-based neurodegenerative gene therapy developer spun out King’s College London, picked up $80m in a series A round co-led by New Enterprise Associates and Monograph Capital yesterday. Johnson & Johnson Innovation – JJDC and F-Prime Capital, respective vehicles for healthcare group Johnson & Johnson and financial services provider Fidelity, contributed to the round,…

The rest of this content is only accessible to Global Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.